UBS has upgraded Viatris Inc. (VTRS) to Buy from Neutral, raising its price target to $18, citing stronger growth prospects, a new product pipeline, continuous cost-cutting, rising profits, and efficient capital allocation. The company recently launched Inpefa in the UAE, the first market outside the U.S., with additional global launches planned. Viatris is expected to discuss its global rollout strategy during its Q4 and full-year 2025 results release on February 26, 2026, ahead of an Investor Event on March 19, 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade
UBS has upgraded Viatris Inc. (VTRS) to Buy from Neutral, raising its price target to $18, citing stronger growth prospects, a new product pipeline, continuous cost-cutting, rising profits, and efficient capital allocation. The company recently launched Inpefa in the UAE, the first market outside the U.S., with additional global launches planned. Viatris is expected to discuss its global rollout strategy during its Q4 and full-year 2025 results release on February 26, 2026, ahead of an Investor Event on March 19, 2026.